Chiropractors in Dededo, GU Accepting Medicare

4 Chiropractors found. Showing 1 - 4

Dr. Amy Gates, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 562 Harmon Loop Rd Ste No129, Dededo, GU 96929 Phone: 671-637-8901    Fax: 671-637-8906

Dr. Gregory John Miller, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 2078 Army Drive, Suite C, Dededo, GU 96929 Phone: 671-637-7926    Fax: 671-637-8887

Hagatna Chiropractic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 562 Harmon Loop Rd Ste No129, Dededo, GU 96929 Phone: 671-637-8901    Fax: 671-637-8906

Dr. Scott Robert Larkin, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 330 W Marine Corps Dr, Ste 4, Dededo, GU 96929 Phone: 671-632-4262    Fax: 671-632-6824

News Archive

RyMed's InVision-Plus IV Connector decreases catheter-related bloodstream infections by 92.6%

Georgia Health Sciences University, Augusta, GA exhibited a poster at the recent 11th National Conference on Cancer Nursing Research in Los Angeles, in which their clinical study showed RyMed Technologies' zero displacement InVision-Plus® IV Connector significantly decreased the incidence of catheter-related bloodstream infections (CR-BSIs) by 92.6% on average when compared to a simple split septum with negative displacement IV connector (Becton-Dickinson Q-Syte®) and a reversed split-septum device with negative displacement IV connector (ICU Medical Clave®).

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.

Chronic pain makes many sufferers contemplate suicide

According to new research patients suffering chronic pain are more likely than others to consider suicide.

Long-term brain-machine interface use could lead to recovery in paraplegic patients

During the 2014 FIFA World Cup opening ceremony, a young Brazilian man, paralyzed from the chest down, delivered the opening kickoff. He used a brain-machine interface, allowing him to control the movements of a lower-limb robotic exoskeleton.

Read more Medical News

› Verified 1 days ago